Search

everythinglearnresearchcommunity

for

Search:↓

User frustrated with lack of results from finasteride and minoxidil for hair loss. Others suggest checking for other health issues, focusing on fitness, and considering alternative treatments.

Hair loss treatments, including microneedling, minoxidil, finasteride and RU58841; the efficacy of these treatments; criticisms of Kevin Mann's content related to his selective data presentation and biases towards certain treatments; and other topics such as DHT being labeled a "trash hormone" and critiques of other hairloss YouTubers.

User experienced shortness of breath, high blood pressure, red eyes, and eye floaters after using RU58841 for hair loss. They warn others to avoid RU58841 and stick to finasteride, minoxidil, and dutasteride.

The post and conversation are about the role of the enzyme 3alpha-hydroxysteroid reductase in hair loss and the potential of compounds like procyanidin B2 and sulforaphane to boost its activity for hair regrowth. Further research is needed to develop effective treatments based on this theory.

An 18-year-old decided to start taking finasteride for hair loss, justifying it by stating that finasteride is the most effective treatment available and that the risk of side effects is low, with clinical trials showing it stops hair loss in 80% of men. The user encourages others not to be deterred by negative forum posts and to consider their own experience and clinical data.

Low-dose oral minoxidil is used for hair loss and does not significantly affect blood pressure but may increase heart rate and cause hypotensive symptoms. Some users experience side effects like palpitations and shortness of breath, while others find it effective; topical minoxidil with tretinoin is also considered.

The conversation discusses whether finasteride's reduction of DHT and increase in scalp testosterone contribute to hair follicle miniaturization. Some participants argue testosterone does not cause miniaturization, while others suggest that even with reduced DHT, other androgens like testosterone may still contribute to hair loss.

A 48-year-old man has been using minoxidil for 15 years and considered finasteride but stopped due to potential side effects. He is concerned about his mental health and the impact of hair loss on self-image, and he encourages support among men experiencing hair loss.

The discussion revolves around the need for future oral DHT blockers for hair loss treatment that don't have the side effects of current options like Finasteride and Dutasteride. One user suggests that the future of hair loss treatment will likely be topical anti-androgens, as they can target hair follicles without affecting the entire system.

A 27-year-old man's experience with taking Finasteride to treat hair loss and the positive side effects he has experienced, such as improved skin. The user also shared their journey of how they were scared away from taking Finasteride due to fear of possible side effects before eventually deciding to take it.

Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.

A user's progress in treating their hair loss using Minoxidil, Finasteride, ketoconazole shampoo, microneedling, omega 3, D3 and Forcapil vitamins over the course of three months. Other users offered support and advice to the original poster.

A user shared their positive experience with finasteride and minoxidil for hair loss, noting significant improvement and regrowth after 1.5 years of treatment, despite initial side effects. They are now happy with their hair and personal life.

The post is about a user who stopped using finasteride for hair loss and shaved his head, receiving positive feedback. The conversation includes discussions on side effects of finasteride, including potential fertility issues, and alternatives like minoxidil, dermarolling, and hair systems.

A 26-year-old male experienced positive results using 1mg Finasteride daily and 2% ketoconazole shampoo for hair loss, with reduced shedding and scalp itch. He reported no significant side effects and recommends early treatment for those in the initial stages of hair loss.

Why androgenic alopecia affects the scalp rather than other body parts, potential explanations for this phenomenon, treatments available to combat hair loss, and the implications of male attractiveness in modern society.

A user is trying to reverse male pattern baldness (MPB) naturally by taking high doses of Vitamin D, improving diet, exercising, reducing stress, and other lifestyle changes, but plans to use finasteride if no results are seen in 60 days. Other users are skeptical, advising medical treatments like finasteride and warning against potential vitamin D overdose and the ineffectiveness of natural remedies for genetic hair loss.

Treatments used to prevent and treat male pattern baldness, the difficulty in finding a permanent cure for hair loss, and the potential financial motivations of companies not wanting to find a cure.

A user did not respond to finasteride, dutasteride, and oral minoxidil for hair loss after four years of treatment and is considering scalp micropigmentation (SMP). Other users suggest the hair loss pattern may indicate alopecia areata and recommend seeing a dermatologist.

A user shared a 60-day progress update on hair regrowth using only 5% Minoxidil foam once daily. Others suggested adding finasteride to address the underlying cause of hair loss and maintain long-term results.

Someone who is starting to experience hair loss and is considering multiple treatments, such as minoxidil, finasteride, dutasteride, and a hair transplant, to manage it. Replies provide advice on how to approach these treatments safely and effectively.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

The conversation suggests that changing diet and lifestyle has little to no effect on male pattern baldness (MPB), which is largely determined by genetics. Some individuals noted personal improvements in hair condition with healthier diets, but the consensus is that diet alone cannot prevent or reverse MPB.

Factors that can cause hair loss other than DHT, such as inflammation and diet, and potential treatments like scalp massages, minoxidil, citrulline, stretches, meditation, iron sulfate/Vitamin C, Vitamin D, protein and Dutasteride.

Dutasteride is more effective than finasteride, has neuroprotective benefits, and may prevent acne. Despite initial concerns about metabolic effects, further research suggests it is safe for most users, especially if not hypogonadal.

The user had high DHT levels after 8 months on dutasteride, questioning the drug's authenticity. They got dutasteride from a legitimate source and will update on progress.

The conversation discusses why DHT (dihydrotestosterone) negatively affects scalp hair but promotes growth elsewhere on the body. Various opinions include genetic predispositions, differences in hair follicle reactions to DHT, and the potential role of Omega-3 in reducing inflammation and promoting hair health.

A user started using RU58841 a month ago after using finasteride and minoxidil for nearly three years, hoping for hair regrowth at the temples. Other users suggest vitamin B supplements and microneedling to improve hair thickness, and one mentions the possibility of a hair transplant for the temples.

The conversation is about future hair loss treatments. Current treatments mentioned include finasteride, minoxidil, and RU58841, with potential future treatments like GT20029, TDM-105795, JW0061, and follicle cloning.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.